

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT4119683

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
EUTHYMICS BIOSCIENCE, INC.	03/02/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NEUROVANCE, INC.
<b>Street Address:</b>	43 THORNDIKE STREET
<b>Internal Address:</b>	SUITE S1-3
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02141
<b>PROPERTY NUMBERS Total: 17</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	11493431
Application Number:	12334432
Application Number:	13207199
Application Number:	13366219
Application Number:	13887367
Application Number:	14494512
Application Number:	14929361
Application Number:	13221892
Application Number:	13425371
Application Number:	13669438
Application Number:	13856431
Application Number:	14802802
Application Number:	13334066
Application Number:	13528940
Application Number:	13751169
Application Number:	13907921
Application Number:	11936016
<b>CORRESPONDENCE DATA</b>	

**Fax Number:** (973)912-5236

***Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** (973)912-5232

**Email:** FILE@HOXPAT.COM

**Correspondent Name:** HOXIE & ASSOCIATES LLC

**Address Line 1:** 75 MAIN STREET

**Address Line 2:** SUITE 203

**Address Line 4:** MILLBURN, NEW JERSEY 07041

<b>ATTORNEY DOCKET NUMBER:</b>	EB-11, 12, 16, 19
--------------------------------	-------------------

<b>NAME OF SUBMITTER:</b>	MARYA K. JONES
---------------------------	----------------

<b>SIGNATURE:</b>	/Marya K. Jones/
-------------------	------------------

<b>DATE SIGNED:</b>	10/28/2016
---------------------	------------

**Total Attachments: 7**

source=Second Euthymics to Neurovance Assignment#page1.tif

source=Second Euthymics to Neurovance Assignment#page2.tif

source=Second Euthymics to Neurovance Assignment#page3.tif

source=Second Euthymics to Neurovance Assignment#page4.tif

source=Second Euthymics to Neurovance Assignment#page5.tif

source=Second Euthymics to Neurovance Assignment#page6.tif

source=Second Euthymics to Neurovance Assignment#page7.tif

## ASSIGNMENT OF PATENT RIGHTS

**THIS ASSIGNMENT OF PATENT RIGHTS** is made effective the 22nd day of December, 2011, by and between EUTHYMICS BIOSCIENCE, INC., a Delaware corporation (the "Assignor"), and NEUROVANCE, INC., a Delaware corporation (the "Assignee").

**WHEREAS**, the Assignor is the holder of the exclusive right, title and interest in and to the patent rights (the "Patent Rights") listed on Appendix "A" hereto;

**WHEREAS**, the Assignor and the Assignee desire that the Assignor transfer the entire and exclusive right, title and interest in and to the Patent Rights;

**NOW, THEREFORE**, in consideration of the premises, the parties agree as follows:

In consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor has assigned and transferred and does hereby assign and transfer to the Assignee and its successors, assigns, and nominees, as the assignee, without any restrictions, reservations or limitations:

(a) the entire and exclusive right, title and interest in said Intellectual Property, including, but not limited to, the Patent Rights and all Letters Patents which may be granted thereon, and all patent applications and Letters Patents that claim priority therefrom or common priority therewith, under the patent laws of any country of the world, including all divisions and continuations thereof, and all reissues, reexaminations, substitutions, registrations, renewals, extensions, and Supplementary Protection Certificates or the like thereof; and

(b) the sole right to file applications for patents under the patent laws of any country of the world in its name, and the sole right to have patents granted on said applications in its name to the full end of term for which said patents may be granted, as fully and entirely as the same would have been held by Assignor, had this assignment not been made, and to enforce said patents with the right to sue for and recover for its own use accrued profits or damages for any and all infringements with respect to which Assignor hereby waives any right to receive any portion thereof.

The Assignor hereby authorizes and requests that Patent Officials in the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, recognize Neurovance, Inc., as the assignee of Assignor's entire right, title and interest in and to the same, for the sole use and enjoyment of Neurovance, Inc., its successors and assigns.

IN TESTIMONY WHEREOF, I, Anthony A. McKinney, the President and Chief Executive Officer of Euthymics Bioscience, Inc., have hereunto set my hand this 2nd day of March, 2015.

EUTHYMICS BIOSCIENCE, INC.,  
a Delaware corporation

By:   
Anthony A. McKinney, President and Chief  
Executive Officer

COMMONWEALTH OF MASSACHUSETTS )  
 ) ss.  
COUNTY OF MIDDLESEX )

Before me, a Notary Public in and for said County and State, on this 2nd day of March, 2015, personally appeared Anthony A. McKinney, to me known to be the identical person who executed the foregoing Assignment and acknowledged to me that he executed the same as his free and voluntary act and deed for the purposes therein set forth.

  
Notary Public  
Commission No: \_\_\_\_\_

My Commission Expires: 10/6/17

**APPENDIX A**

<b>APPLICATION NUMBER</b>	<b>COUNTRY</b>	<b>TITLE</b>
2006275870	Australia	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
P10613943-4	Brazil	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
2,659,215	Canada	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
200680035426.4	China	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
06788541.8	Europe	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
08111850.8	Hong Kong	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
08113526.8	Hong Kong	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
1738/DELNP/2008	India	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
W00200800242	Indonesia	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
189008	Israel	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS

APPLICATION NUMBER	COUNTRY	TITLE
2008-524100	Japan	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
1020087004765	Korea	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
Mx/a/2008/001187	Mexico	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
566236	New Zealand	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
592836	New Zealand	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
20081016	Norway	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
PCT/US2006/029006		NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
12008500187	Philippines	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
2008107336	Russia	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
200800684-3	Singapore	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
2008/01825	South Africa	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS

APPLICATION NUMBER	COUNTRY	TITLE
60/703,364	U.S.	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
11/493,431	U.S.	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
12/334,432	U.S.	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
13/207,199	U.S.	NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS
PI0718654-1	Brazil	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
2,705,457	Canada	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
07861821.2	Europe	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
3695/DELNP/2009	India	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
2009-536293	Japan	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
1020097011844	Korea	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
PCT/US2007/023506		NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE

APPLICATION NUMBER	COUNTRY	TITLE
2009121553	Russia	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
2009/03935	South Africa	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
60/857,667	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,007	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,016	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
11/936,722	U.S.	NOVEL ARYLBICYCLO[3.1.0]HEXYLAMINES AND METHODS AND COMPOSITIONS FOR THEIR PREPARATION AND USE
08768192.0	Europe	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
10108387.2	Hong Kong	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
PCT/US2008/007116		NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
60/933,631	U.S.	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
12/135,053	U.S.	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS



APPLICATION NUMBER	COUNTRY	TITLE
12/895,788	U.S.	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES. METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
13/048,852	U.S.	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES. METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
13/221,892	U.S.	NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES. METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
61/574,231	U.S.	USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
13/334,066	U.S.	USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS